Key statistics
As of last trade Arrowhead Pharmaceuticals Inc (HDP1:FRA) traded at 52.22, -18.58% below its 52-week high of 64.14, set on Jan 06, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 52.22 |
|---|---|
| High | 52.22 |
| Low | 52.22 |
| Bid | 51.90 |
| Offer | 53.44 |
| Previous close | 54.02 |
| Average volume | 1.34k |
|---|---|
| Shares outstanding | 140.03m |
| Free float | 134.68m |
| P/E (TTM) | 41.87 |
| Market cap | 9.03bn USD |
| EPS (TTM) | 1.54 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:10 GMT.
More ▼
Press releases
- Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
- Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
- Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
- Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
- Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
- Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
- Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
More ▼
